Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SA55
- Development stage
- Phase 2
- Lead developer
- Sinovac Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Injection, Intranasal
01
Overview
SA55 is a broad-spectrum neutralizing monoclonal antibody developed for the prevention and treatment of COVID-19. It targets the SARS-CoV-2 spike (S) protein, acting as a modulator to neutralize the virus. The drug has been formulated both as an injection and as a nasal spray. Clinical trials have demonstrated favorable pharmacokinetics, with a half-life of approximately 103 days following injection and potential utility in preventing COVID-19 infection[1][3][6]. The antibody was initially developed by Peking University and is being further developed by companies including Sinovac Biotech, Shandong Kexing Bioproducts, and Beijing Kexing Zhongwei Biotechnology[4][5][6]. As of April 2025, SA55 has reached Phase 2 clinical trials for COVID-19 indications[4][6].
- Other names
- 新冠中和抗体SA55
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on SA55.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SA55.